Shamburg News · 8-K filed Nov 10, 2026, 8:21 AM EST

MaxCyte Agrees to Acquire Akron Bio; Reports Q3 2026 Revenue of $10.2 Million

MXCT · MAXCYTE, INC.

  • Material agreement
  • Acquisition
  • Earnings
  • Financing
  • Reg FD disclosure
  • Materiality: high

On November 9, 2026, MaxCyte entered into a Securities Purchase Agreement to acquire Akron BioProducts LLC for $105.0 million in cash, 20,639,733 shares of common stock, and $20.0 million in guaranteed deferred cash payments. On November 10, 2026, the company reported third quarter 2026 total revenue of $10.2 million and a net loss of $4.8 million, and raised its full-year 2026 total revenue guidance to at least $34.5 million. The Stock Consideration will be issued to the Sellers at closing under Section 4(a)(2), and the closing is expected before the end of 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 2.02, 3.02, 7.01, accession 0001104659-26-124829.

Written from the filing by Shamburg Markets. Figures are as reported by the company.